Neuromuscular junction in health and disease

British Journal of Anaesthesia

Volumn 99, Issue 1, 2007, Pages 132-138

  Hirsch, Nicholas P ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Myasthenia gravis; Nerve; Transmission

Indexed keywords

3,4 DIAMINOPYRIDINE; ACETYLCHOLINE; ACETYLCHOLINESTERASE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTITOXIN; ATRACURIUM; AZATHIOPRINE; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; EDROPHONIUM CHLORIDE; ENFLURANE; HALOTHANE; HYDROCORTISONE; IMMUNOGLOBULIN; INHALATION ANESTHETIC AGENT; ISOFLURANE; MIVACURIUM; NEOSTIGMINE; NEUROMUSCULAR BLOCKING AGENT; PENICILLAMINE; PREDNISOLONE; PYRIDOSTIGMINE; SEVOFLURANE; SUXAMETHONIUM; VECURONIUM;

ANESTHESIA; ARTIFICIAL VENTILATION; BOTULISM; CONGENITAL MYASTHENIC SYNDROME; DEBRIDEMENT; DRUG WITHDRAWAL; EATON LAMBERT SYNDROME; EPIDURAL ANESTHESIA; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MYASTHENIA GRAVIS; MYOKYMIA; NEUROMUSCULAR JUNCTION DISORDER; PLASMAPHERESIS; POSTOPERATIVE CARE; POSTSYNAPTIC POTENTIAL; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; REVIEW; THYMECTOMY; WOUND INFECTION;

EID: 34447503928     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aem144     Document Type: Review

References (47)

1. Akpolat N, Tilgen H, Gursoy F, Saydam S, Gurel A. Thoracic epidural anaesthesia and analgesia with bupivacaine for transsternal thymectomy for myasthenia gravis. Eur J Anaesthesiol 1997; 14: 220-3
2. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 2006; 354: 462-71
3. Baraka A. Anaesthesia and myasthenia gravis. Can J Anaesth 1992; 39: 476-86
4. Baraka A, Baroody M, Yazbeck V. Repeated doses of suxamethonium in the myasthenic patient. Anaesthesia 1993; 28: 782-4
5. Baraka A. Onset of neuromuscular blockade in myasthenia patients. Br J Anaesth 1992; 69: 227-8
6. Baraka A. Anesthesia and critical care of thymectomy for myasthenia gravis. Chest Surg Clin North Am 2001; 330: 1797-810
7. Bell CF, Florence AM, Hunter JM, Jones RS, Utting JE. Atracurium in the myasthenic patient. Anaesthesia 1984; 39: 961-8
8. Biarnes A, Rochera MI. Lambert-Eaton (myasthenic) syndrome: pre-anaesthetic treatment with intravenous immunoglobulins. Anaesthesia 1996; 51: 797
9. Bowman WC. Prejunctional mechanisms involved in neuromuscular transmission. In: Booij LHDJ, ed. Neuromuscular Transmission. London: BMJ Publishing Group, 1996; 1-27
10. Brown TCK, Gerbert R, Meretoja OA, Shield LK. Myasthenia gravis in children and its anaesthetic implications. Anaesth Intensive Care 1990; 18: 466-72
11. Caya JG, Agni R, Miller JE. Clostridium botulinum and the clinical laboratorian. Arch Pathol Lab Med 2004, 128: 653-62
12. Colebatch JG, Wolff AH, Gilbert RJ, Mathias CJ, Smith SE, Hirsch N. Slow recovery from severe foodborne botulism. Lancet 1989; 2: 1216-7
13. Eisenkraft JB, Papatestas AE, Kahn CH, Mora CT, Fagerstrom R, Genkins G. Predicting the need for postoperative mechanical ventilation in myasthenia gravis. Anesthesiology 1986; 65: 79-82
14. Eisenkraft JB, Book J, Mann SM, Papatestas AE, Hubbard M. Resistance to succinylcholine in myasthenia gravis: A dose-response study. Anesthesiology 1988; 69: 760-3
15. Engel AG, Ohno K, Shen X-M, Sine SM. Congenital myasthenic syndromes: multiple molecular targets at the neuromuscular junction. Ann N Y Acad Sci 2003; 998: 138-60
16. Fukunaga H, Engel AG, Osame M, Lambert EH. Paucity and disorganisation of presynaptic membrane active zones in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1982; 5: 686-97
17. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7: 365-8
18. Hunter JM, Bell CF, Florence AM, Jones RS, Utting JE. Vecuronium in the myasthenic patient. Anaesthesia 1985; 40: 848-53
19. Itoh H, Shibata K, Nitta S. Difference in sensitivity to vecuronium between patients with ocular and generalized myasthenia gravis. Br J Anaesth 2001; 87: 885-9
20. Kiran U, Choudhury M, Saxena N, Kapoor P. Sevoflurane as a sole anaesthetic agent for thymectomy in myasthenia gravis. Acta Anaesth Scand 2000; 44: 351-3
21. Koh LKD, Ip-Yam PC, Tan ASA. Perioperative management of a patient with congenital myasthenic syndrome for elective Caesarean section. Sing Med J 2001; 42: 61-3
22. Le Gars L, Clerc D, Cariou D, Lavabre C, Metral S, Bisson M. Systemic juvenile rheumatoid arthritis and associated Isaacs' syndrome. J Rheumatol 1997; 24: 178-80
23. Lindstrom J. Acetylcholine receptors and myasthenia. Muscle Nerve 2000; 23: 453-77
24. Lindstrom J. Nicotinic acetylcholine receptors of muscles and nerves: comparison of their structures, functional roles and vulnerability to pathology. Ann N Y Acad Sci 2003; 998: 41-52
25. Lumb AB, Calder I. Cured myasthenia and neuromuscular blockade. Anaesthesia 1989; 44: 828-30
26. Maselli RA. Pathogenesis of human botulism. Ann N Y Acad Sci 1998; 841: 122-39
27. Maselli RA, Bakshi N. Botulism. Muscle Nerve 2000; 23: 1137-44
28. McBeth C, Watkins TGL. Isoflurane for sedation in a case of congenital myasthenia gravis. Br J Anaesth 1996; 77: 672-4
29. Morgan PJ. Peripartum management of a patient with Isaacs' syndrome. Can J Anaesth 1997; 44: 1174-7
30. Naguib N, Flood P, McArdle JJ, Brenner HR. Advances in the neurobiology of the neuromuscular junction. Anesthesiology 2002; 96: 202-31
31. Newsom-Davis J, Buckley C, Clover L, et al. Autoimmune disorders of neuronal potassium channels. Ann N Y Acad Sci 2003; 998: 202-10
32. Newsom-Davis J, Mills KR. Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Brain 1993; 116: 453-69
33. Nilsson E, Paloheimo M, Muller K, Heinonen J. Halothane-induced variability in the neuromuscular transmission of patients with myasthenia gravis. Acta Anaesth Scand 1989; 33: 395-401
34. Nilsson E, Muller K. Neuromuscular effects of isoflurane in patients with myasthenia gravis. Acta Anaesth Scand 1990; 34: 126-31
35. Ohno K, Engel AG, Brengman JM, et al. The spectrum of mutations causing endplate acetylcholinesterase deficiency. Ann Neurol 2000; 47: 162-70
36. O'Neill JH, Murray NMF, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988; 111: 577-96
37. Paterson IG, Hood JR, Russell SH, Weston MD, Hirsch NP. Mivacurium in the myasthenic patient. Br J Anaesth 1994; 73: 494-8
38. Paton WDM, Waud DR. The margin of safety of neuromuscular transmission. J Physiol 1967; 191: 59-90
39. Ruff RL. Neurophysiology of the neuromuscular junction: Overview. Ann N Y Acad Sci 2003; 998: 1-10
40. Russell SH, Hood JR, Campkin NT, Hirsch NP. Neuromuscular effects of enflurane in myasthenia gravis. Br J Anaesth 1993; 71: 766P
41. Sanders DB. Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 2003; 998: 500-8
42. + channels of peripheral nerves. Ann Neurol 1995; 38: 714-22
43. Small S, Ali HH, Lennon VA, Brown RH Jr, Carr DB, de Armendi A. Anesthesia for an unexpected Lambert-Eaton myasthenic syndrome with autoantibodies and occult small cell lung carcinoma. Anesthesiology 1992; 76: 142-5
44. Smith AG, Wald J. Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine. Neurology 1996; 46: 1143-5
45. Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology 2000; 54: 2176-8
46. Tripathi M, Kaushik S, Dubey P. The effect of use of pyridostigmine and requirement of vecuronium with myasthenia gravis. J Postgrad Med 2003; 49: 311-5
47. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001; 357: 2122-8